2013
Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis
Bignotti E, Tassi RA, Calza S, Ravaggi A, Rossi E, Donzelli C, Todeschini P, Romani C, Bandiera E, Zanotti L, Carnazza M, Quadraro F, Tognon G, Sartori E, Pecorelli S, Roque DM, Santin AD. Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis. Journal Of Translational Medicine 2013, 11: 162. PMID: 23819652, PMCID: PMC3706350, DOI: 10.1186/1479-5876-11-162.Peer-Reviewed Original ResearchConceptsOvarian carcinomaNormal ovariesMammaglobin APrognostic markerLipophilin ALipophilin BPatients' clinico-pathological featuresMultivariate Cox regression analysisMammaglobin B mRNANeoplastic ovarian tissuesProgression-free survivalDisease-free survivalProtein expressionCox regression analysisLow tumor gradeClinico-pathological featuresIndependent prognostic markerUnivariate survival analysisOvarian carcinoma samplesAggressive tumor phenotypeGene overexpressionParaffin-embedded tumorsConclusionsThe present studyReal-time reverse transcription PCRQuantitative real-time reverse transcription PCR
2012
Prognostic Significance of Vascular Endothelial Growth Factor Serum Determination in Women with Ovarian Cancer
Bandiera E, Franceschini R, Specchia C, Bignotti E, Trevisiol C, Gion M, Pecorelli S, Santin AD, Ravaggi A. Prognostic Significance of Vascular Endothelial Growth Factor Serum Determination in Women with Ovarian Cancer. International Scholarly Research Notices 2012, 2012: 245756. PMID: 22792477, PMCID: PMC3390037, DOI: 10.5402/2012/245756.Peer-Reviewed Original ResearchIndependent prognostic factorPrognostic factorsPrognostic significanceOvarian cancerSerum vascular endothelial growth factor (VEGF) levelsVascular endothelial growth factor levelsPresence of ascitesLymph node involvementResidual tumor sizeSubgroup of patientsGood prognostic markerGrowth factor levelsPotential prognostic significanceMEDLINE/PubMedSVEGF levelsFIGO stageNode involvementOverall survivalTumor sizeTumor gradeEligible studiesPatient outcomesPrognostic markerInclusion criteriaPrognostic variables